Our Products
Metopirone® (Metopiron®, Cormeto®, Metycor®),
Ketoconazole HRA™ and Lysodren® are developed by HRA Pharma Rare Diseases.
Therapies for Cushing’s syndrome and adrenocortical carcinoma.
HRA Pharma Rare Diseases therapies were developed to meet the needs of patients with rare and ultra-rare diseases for a range of medical conditions. Regulatory status and access to our products may vary depending on the country.

If you would like further information on any of our products, please contact us.
Metopirone Logo
Metopirone® 
(metyrapone)
The name of our products may vary depending on the country. It may be also called Metopiron®, Cormeto® or Metycor®. Click on the links below dependent on country for further information on the Summary of Product Characteristics (SmPC):

Ketoconazole HRA Logo
Ketoconazole HRA™ 
(ketoconazole)
The following information is intended only for healthcare professionals outside of the United States. Click on the link below for further information on the Summary of Product Characteristics (SmPC):

Lysodren Logo
Lysodren® 
(mitotane)
Click on the links below dependent on country for further information on the Summary of Product Characteristics (SmPC):